Vertex’s CRISPR therapy CASGEVY eliminates symptoms in young kids, eyes FDA expansion
Vertex Pharmaceuticals (NASDAQ:VRTX) announced highly anticipated clinical data demonstrating that its CRISPR-based gene-editing therapy, CASGEVY, matches its highly successful adult profile when used in younger children.










